<span item_type="fundamental" item_id="7f9b3bc8a4000751083ebf8ebd58e2e5" counter_id="ST/US/ELAB" env="prod"></span><span item_type="announcement" item_id="548928589533747457" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -2.41.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Discontinued Operations (Skincare Business)</strong>: Revenue for the six months ended June 30, 2025, was $152,381, compared to $1,220,093 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840563/000121390025075234/ea0252380-10q_pmgc.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the six months ended June 30, 2025, the net loss from continuing operations was -$2,160,301, compared to -$1,097,032 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840563/000121390025075234/ea0252380-10q_pmgc.htm"></span></li><li><strong>Total Net Loss</strong>: For the six months ended June 30, 2025, the total net loss was -$2,170,810, compared to -$2,809,741 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840563/000121390025075234/ea0252380-10q_pmgc.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses for the six months ended June 30, 2025, were $2,215,242, compared to $1,356,216 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840563/000121390025075234/ea0252380-10q_pmgc.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Cash flows used in operating activities for the six months ended June 30, 2025, were -$2,693,714, compared to -$3,104,757 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840563/000121390025075234/ea0252380-10q_pmgc.htm"></span></li><li><strong>Free Cash Flow</strong>: Not explicitly stated, but cash used in investing activities was -$18,479 for the six months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840563/000121390025075234/ea0252380-10q_pmgc.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Research and Development Expenses</strong>: For the six months ended June 30, 2025, R&amp;D expenses were $99,108, compared to $55,553 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840563/000121390025075234/ea0252380-10q_pmgc.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: PMGC Holdings Inc. plans to increase revenue through PMGC Capital LLC by acquiring and managing undervalued assets and investments. The company also aims to advance clinical development for NorthStrive Biosciences, Inc.’s clinical assets toward IND applications.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840563/000121390025075234/ea0252380-10q_pmgc.htm"></span></li><li><strong>Non-Core Business</strong>: The company is evaluating potential opportunities such as out-licensing biotechnology applications, potential spin-offs, and creating new publicly traded companies, such as SPACs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1840563/000121390025075234/ea0252380-10q_pmgc.htm"></span></li></ul>

PMGC | 10-Q: FY2025 Q2 EPS: USD -2.41